Expression of matrix metalloproteinase-9 in the neoplastic and interstitial inflammatory infiltrate cells in gastric cancer

Folia Histochemica et Cytobiologica

Volumn 47, Issue 3, 2009, Pages 491-496

  Mroczko, Barbara ^a   Łukaszewicz Zaja̧c, Marta ^a   Guzińska Ustymowicz, Katarzyna ^a   Gryko, Mariusz ^a   Czyzewska, Jolanta ^a   Kemona, Andrzej ^a   Kȩdra, Bogusław ^a   Szmitkowski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Gastric cancer; Matrix metalloproteinases; MMP 9 expression

Indexed keywords

GELATINASE B;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER TISSUE; CELL INFILTRATION; DISTANT METASTASIS; ENZYME SYNTHESIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STOMACH CANCER;

EID: 77149142290     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-009-0070-7     Document Type: Article

References (26)

1. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009;472:467-477.
2. Samson PS, Escovidal LA, Yrastorza SG, Veneracion RG, Nerves MY. Re-study of gastric cancer: analysis of outcome. World J Surg. 2002;26:428-433.
3. Shim KN, Jung SA, Joo YH, Yoo K. Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. J Gastroenterol. 2007; 42:120-128.
4. Schwartz GK. Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations. Semin Oncol. 1996;23:316-324.
5. Wagenaar-Miller RA, Gorden L, Matrisian LM. Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev. 2004;23:119-135.
6. Lebensztejn DM, Skiba E, Sobaniec-£otowska ME, Kaczmarski M. Matrix metalloproteinases and their tissue inhibitors in children with chronic hepatitis B treated with lamivudine. Adv Med Sci. 2007;52:114-119.
7. Nabeshima K, Inoue T, Shimao Y et al. Matrix metalloproteinases in tumor invasion: Role for cell migration. Pathol International. 2002;52:255-264.
8. Kabashima A, Maehara Y, Kakeji Y, Baba H, Koga T, Sugimachi K. Clinicopathological features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis. Clin Cancer Res. 2000;6:3581-3584.
9. Yasumitsu H, Miyazaki K, Umenishi F, Koshikawa N, Umeda M. Comparison of extracellular matrix-degrading activities between 64-kDa and 90-kDa gelatinases purified in inhibitor-free forms from human schwannoma cells. J Biochem. 1992; 111:74-80.
10. Czyzewska J, Guziñska-Ustymowicz K, Kemona A, Bandurski R. The expression of matrix metalloproteinase 9 and cathepsin B in gastric carcinoma is associated with lymph node metastasis, but not with postoperative survival. Folia Histochem Cytobiol. 2008;46:57-64.
11. De Mingo M, Morán A, Sánchez-Pernaute Aet al. Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma. Hepatogastroenterology. 2007;54:315-319.
12. Seo YS, Park JJ, Kim JH et al. Usefulness of MMP-9/TIMP-1 in predicting tumor recurrence in patients undergoing curative surgical resection for gastric carcinoma. Dig Dis Sci. 2007;52:753-759.
13. Tan SY, Wang JY, Shen L, Luo HS, Shen ZX. Relationship between preoperative staging by endoscopic ultrasonography and MMP-9 expression in gastric carcinoma. World J Gastroenterol. 2007;13:2108-2112.
14. Zhang S, Li L, Lin JY, Lin H. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol. 2003;9:899-904.
15. Gao ZL, Zhang C, Du GY, Lu ZJ. Clinical significance of changes in tumor markers, extracellular matrix, MMP-9 and VEGF in patients with gastric carcinoma. Hepatogastroenterology. 2007;54:1591-1595.
16. Koyama S. Enhanced cell surface expression of matrix metalloproteinases and their inhibitors, and tumor-induced host response in progression of human gastric carcinoma. Dig Dis Sci. 2004;49:1621-1630.
17. Liotta LA, Kohn EC. The microenvironment of the tumorhost interface. Nature. 2001;411:375-379.
18. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332-337.
19. Gonzalez LO, Pidal I, Junquera S et al. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer. 2007;97:957-963.
20. Yoshikawa T, Tsuburaya A, Kobayashi O et al. Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer. Cancer Lett. 2000;151:81-86.
21. Mroczko B, Kozłowski M, Groblewska M et al. Expression of matrix metalloproteinase-9 in the neoplastic and interstitial inflammatory infiltrate cells in the different histopathological types of esophageal cancer. Folia Histochem Cytobiol. 2008; 46:471-478.
22. th edition. New York: Willey-Liss. 1997.
23. Seiki M, Yana I. Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci. 2003;94:569-574.
24. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
25. Daniel D, Chiu C, Giraudo E et al. CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res. 2005;65:2018-2025.
26. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135-49.